Psoriatic arthritis, treatment response, and changes in quality of life in a population treated at a reference center in Medellín
Article Sidebar
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Societal impact
Main Article Content
Abstract
Objective: psoriatic arthritis, as a manifestation of psoriatic disease, is a chronic and inflammatory condition, with articular symptoms, dactylitis, enthesitis and changes in the skin and nails. Despite the existence of various treatment recommendations, the factors determining the treatment response in the Latin American population have not been clarified. The aim of this study was to describe the characteristics of patients with psoriatic arthritis and identify the differences in the response to treatment and its impact on quality of life in a medical center in Medellín.
Methods: medical records of 114 patients with psoriatic disease and arthritis were analyzed to evaluate sociodemographic, clinical, treatment, and clinimetric variables. A univariate analysis was carried out for quantitative and qualitative variables and a bivariate analysis was carried out to evaluate differences between variables, comparing them using the Chi-squared test.
Results: a significant difference was observed between affiliation to the EPS contribu-tory regime (p 0.041) and initial treatment with biologicals (p 0.044). There is a negative association between psoriasis vulgaris and axial arthritis (OR 0.11; 95 % CI 0.0269–0.476; p< 0.001) and between nail psoriasis and axial arthritis (OR 0.20; 95 % CI 0.0567–0.767; p=0.011). High levels of total and LDL cholesterol were related to a lower probability of achieving a 90 % of improvement according to the scale PASI 90 (p<0.05). Lower hemoglobin is related to worse therapeutic response (p<0.05).
Conclusion: men were the most affected with a higher association with comorbidities and cardiovascular risk. Methotrexate is the most used medication associated with an improvement in quality of life. Biological medications were positively associated with achieving a PASI 90 goal.
Article Details
References
Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
Fernández-Ávila DG, Prada-Vanegas JD, De la Espriella MC, Barahona-Correa JE, Charry LP, Cuellar I. Frequency of use and annual costs of biological therapy for psoriasis in Colombia in 2019. International Journal of Dermatology. 2024;63(11):e296-301.
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-15.
Lorenzo JA, Pardo E, Pino M, Colazo M, Queiro MR. Artritis psoriásica: interacción entre enfermedades cardiometabólicas y la actividad inflamatoria de la enfermedad. Reumatología Clínica. 2022;18(7):387–92.
Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019;8:1665.
Ng BCK, Jadon DR. Unmet needs in psoriatic arthritis. Best Practice & Research Clinical Rheumatology. 2021;35(2):101693.
Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: A literature review. Best Practice & Research Clinical Rheumatology. 2021;35(2):101692.
Aringer M, Brinks R, Dörner T, Daikh D, Mosca M, Ramsey-Goldman R, et al. European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Ann Rheum Dis. 2021;80(6):775–81.
Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Up-dated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-479.
Fernández-Ávila DG, Arredondo González AM, Arteaga CE, Jaramillo Arroyave D, Cortés Correa CI, Chiquito S, et al. Clinical practice guideline for the treatment of psoriatic arthritis in Colombia. Revista Colombiana de Reumatología. 2023;30:S55-64.
Coates LC, Orbai AM, Azevedo VF, Cappelleri JC, Steinberg K, Lippe R, et al. Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. Health Qual Life Outcomes. 2020;18(1):173.
Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Review of Clinical Immunology. 2018;14(5):405–17.
Von EE, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Declaración de la iniciativa STROBE (Strengthening the Reporting of Observational Studies in Epidemiology): directrices para la comunicación de estudios observacionales. Rev Esp Salud Publica. 2008;82(3):251-259.
Registro Iberoamericano de Espondiloartritis (RESPONDIA): ¿qué es, ¿cómo surgió, quiénes somos y qué hacemos? Metodología general [Internet]. [cited 2023 May 19]. Available from: https://www.reumatologiaclinica.org/es-pdf-13130691.
Eder L, Haddad A, Rosen CF, Lee K, Chandran V, Cook R, et al. The Incidence and Risk Factors for Psoriatic Arthritis in Patients with Psoriasis: A Prospective Cohort Study. Arthritis Rheumatol. 2016;68(4):915-923.
Moll JMH, Wright V. Psoriatic arthritis. Seminars in Arthritis and Rheumatism. 1973;3(1):55–78.
Khan M, Schentag C, Gladman DD. Clinical and Radiological Changes During Psoriatic Arthritis Disease Progression. J Rheumatol. 2003;30(5):1022-6.
Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study. Arthritis Rheum. 2009;61(2):233–9.
Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: Not a passive bystander. Autoimmunity Reviews. 2014;13(9):981–1000.
Pezzolo E, Naldi L. The relationship between smoking, psoriasis and psoriatic arthritis. Expert Review of Clinical Immunology. 2019;15(1):41–8.
Polachek A, Touma Z, Anderson M, Eder L. Risk of Cardiovascular Morbidity in Patients with Psoriatic Arthritis: A Meta-Analysis of Observational Studies: Cardiovascular Morbidity in PsA. Arthritis Care & Research. 2017;69(1):67–74.
Nas K, Capkin E, Dagli AZ, Cevik R, Kilic E, Kilic G, et al. Gender specific differences in patients with psoriatic arthritis. Modern Rheumatology. 2017;27(2):345–9.
Eder L, Thavaneswaran A, Chandran V, Gladman DD. Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. Ann Rheum Dis. 2013;72(4):578–82.
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376(10):957–70.
Felbo SK, Terslev L, Østergaard M. Imaging in peripheral and axial psoriatic arthritis: contributions to diagnosis, follow-up, prognosis and knowledge of pathogenesis. Clin Exp Rheumatol. 2018;36 Suppl 114(5):24–34.
Bonfiglioli R, Conde RA, Sampaio-Barros PD, Louzada-Junior P, Donadi EA, Bertolo MB. Frequency of HLA-B27 alleles in Brazilian patients with psoriatic arthritis. Clin Rheumatol. 2008;27(6):709–12.
Ayan G, Aydin SZ, Kimyon G, Ozisler C, Tinazzi I, Dogru A, et al. PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis. Rheumatology. 2021;60(4):1755–62.
Toloza SMA, Valle-Oñate R, Espinoza LR. Psoriatic Arthritis in South and Central America. Curr Rheumatol Rep. 2011;13(4):360–8.
López-Medina C, Chevret S, Molto A, Sieper J, Duruöz T, Kiltz U, et al. Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study. RMD Open. 2021;7(3):e001728.
Fathia Ehmouda Z. Clinical Patterns of Psoriatic Arthritis and the Relationship between Psoriasis Skin Severity and Joint Activity in Libya. J Rheum Dis Treat. 2021;7(1):089.